Vecima Announces Creation of Office of the CTO and Executive Leadership Changes
20.7.2020 18:50:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) announced today that it has made several organizational changes across the executive leadership team in alignment with the company’s growth and operational objectives.
Mr. Clay McCreery has been appointed Chief Operating Officer. Mr. McCreery previously served as Chief Revenue Officer for Vecima, as well as managing operations for the Content Delivery & Storage business unit. He joined Vecima through the acquisition of Concurrent Technology in 2017. Prior to joining Concurrent, Mr. McCreery was Senior Vice President of Sales of North America at ARRIS for 14 years. During his tenure there, he helped integrate several key acquisitions enabling ARRIS’ market share growth in Access Technologies, DOCSIS Services, and Content Delivery. “This is a pivotal time for the company and the industries we serve. I am thrilled to be part of an organization with the vision and determination to help our customers transition their networks for next-generation services,” said Mr. McCreery.
Mr. Colin Howlett has been appointed Chief Technology Officer and will lead the newly created Office of the CTO. Mr. Howlett previously served as Vice President of Architecture at Vecima, and his tenure with the company spans 23 years, leading engineering and architecture teams. His technical expertise spans a wide breadth, including wireless, wireline, RF, and software engineering. “Throughout my previous roles at Vecima, the aspect I’ve enjoyed most is partnering with the customers we serve to develop unique and compelling solutions to their technical challenges,” said Mr. Howlett. “I look forward to leading a team of world-class technology experts and industry thought leaders as we expand our reach.”
Mr. Kyle Goodwin has been promoted to SVP & General Manager of the Content Delivery & Storage business unit. Mr. Goodwin previously led Concurrent Technology’s research and development portfolio of products through a time of transition in the service provider industry. Prior to joining Concurrent, he spent time in the telecommunications, financial technology, and insurance industries with Motorola, PrimeRevenue, S1 Corporation, and Aflac. Mr. Goodwin is also a Steering Board Member of the DVB Project, an industry-led consortium defining the global standard for digital television.
Mr. Ryan Nicometo has been promoted to SVP & General Manager of the Video & Broadband Solutions business unit. Mr. Nicometo, who also joined Vecima from the acquisition of Concurrent Technology, brings 21 years of experience in the service provider space to his role. Prior to joining Concurrent, he held leadership roles at ARRIS Group, CCI Systems, and Motorola. While at Motorola and ARRIS, he helped integrate technology and talent from several acquisitions across roles in sales and product management.
Mr. Goodwin and Mr. Nicometo will report to Mr. McCreery in their new roles with the company.
“Both Ryan and Kyle have been key members of the management team and have been significant contributors in the success of the company over the last several years,” said Mr. McCreery.
“I am very excited to have Clay, Colin, Kyle, and Ryan take on expanded roles within the Vecima leadership team as we continue to execute on our strategy to serve our global service provider and broadcast customers with a powerful suite of products and technologies that fuel a more connected world,” said Mr. Sumit Kumar, President and Chief Executive Officer of Vecima. “Vecima is positioned for growth and investing in the futures of the industries we serve.”
About Vecima
Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high-capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005209/en/
Contact information
Vecima Networks
Investor Relations – 250-881-1982
invest@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom